ChiCTR2100041888 版本V1.4 版本创建时间2021/03/27 21:28:51 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2100041888 

最近更新日期:

Date of Last Refreshed on:

2021-03-27 21:23:32 

注册时间:

Date of Registration:

2021-01-09 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

云南地区2型糖尿病血管病变相关风险因素的研究

Public title:

Analysis of risk factors in vascular complications of type 2 diabetes in Yunnan province

注册题目简写:

English Acronym:

研究课题的正式科学名称:

云南地区2型糖尿病血管病变相关风险因素的研究

Scientific title:

Analysis of risk factors in vascular complications of type 2 diabetes in Yunnan province

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

周园媛 

研究负责人:

杨莹 

Applicant:

Zhou Yuan yuan 

Study leader:

Yang Ying 

申请注册联系人电话:

Applicant telephone:

+86 13577751233

研究负责人电话:

Study leader's
telephone:

+86 13808792563

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

943157026@qq.com

研究负责人电子邮件:

Study leader's E-mail:

yangying2072@163.om

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

云南省昆明市青年路176号

研究负责人通讯地址:

云南省昆明市青年路176号

Applicant address:

176 Qingnian Road, Wuhua District, Kunming, Yunnan, China

Study leader's address:

176 Qingnian Road, Wuhua District, Kunming, Yunnan, China

申请注册联系人邮政编码:

Applicant postcode:

650021

研究负责人邮政编码:

Study leader's postcode:

650021

申请人所在单位:

云南省第二人民医院

Applicant's institution:

The Second People's Hospital of Yunnan

研究负责人所在单位:

云南省第二人民医院

Affiliation of the Leader:

The Second People's Hospital of Yunnan

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2020049

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

云南省第二人民医院医学伦理委员会

Name of the ethic committee:

Medical Ethics Committee of the Second People's Hospital of Yunnan Province

伦理委员会批准日期:

Date of approved by ethic committee:

2020-04-26 00:00:00

伦理委员会联系人:

陈麟

Contact Name of the ethic committee:

Chen Lin

伦理委员会联系地址:

云南省昆明市青年路176号

Contact Address of the ethic committee:

176 Qingnian Road, Wuhua District, Kunming, Yunnan, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 13577751233

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

云南省第二人民医院

Primary sponsor:

The Second People's Hospital of Yunnan

研究实施负责(组长)单位地址:

云南省昆明市青年路176号

Primary sponsor's address:

176 Qingnian Road, Wuhua District, Kunming, Yunnan, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

云南

市(区县):

昆明

Country:

China

Province:

Yunnan

City:

Kunming

单位(医院):

云南省第二人民医院

具体地址:

青年路176号

Institution
hospital:

The Second People's Hospital of Yunnan

Address:

176 Qingnian Road, Wuhua District

经费或物资来源:

云南省内分泌临床医学中心,No. ZX2019-02-02

Source(s) of funding:

the Endocrine Clinical Medical Center of Yunnan Province, No. ZX2019-02-02

研究疾病:

2型糖尿病  

Target disease:

type 2 diabetes

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

析因分组(即根据危险因素或暴露因素分组) 

Study design:

Factorial 

研究目的:

评估云南地区2型糖尿病血管病变的相关风险因素。  

Objectives of Study:

Evaluation of risk factors related to vascular disease of type 2 diabetes in Yunnan.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

所有患者均符合1999年WHO制订的T2DM诊断标准。

Inclusion criteria

All patients meet the diagnostic criteria for T2DM set by the WHO in 1999.

排除标准:

1. 年龄≤18岁;
2. 糖尿病急性并发症(包括糖尿病酮症酸中毒,糖尿病高渗状态);
3. 严重的心脑血管疾病(包括心衰,急性心肌梗死,心绞痛,急性脑梗死,脑出血等);
4. 恶性肿瘤;
5. 严重肝功能不全;
6. 妊娠;
7. 各种急慢性感染性疾病。

Exclusion criteria:

1. Aged <= 18 years;
2. Acute complications of diabetes (including diabetic ketoacidosis, diabetic hypertonic state);
3. Severe cardiovascular and cerebrovascular diseases (including heart failure, acute myocardial infarction, angina pectoris, acute cerebral infarction, cerebral hemorrhage, etc.);
4. Malignant tumor;
5. Severe liver insufficiency;
6. Pregnancy;
7. Various acute and chronic infectious diseases.

研究实施时间:

Study execute time:

From 2021-01-01 00:00:00 To 2024-12-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2021-01-01 00:00:00 To 2024-12-01 00:00:00

干预措施:

Interventions:

组别:

无血管病变组vs血管病变组

样本量:

800

Group:

vascular disease group vs non vascular disease group

Sample size:

干预措施:

干预措施代码:

Intervention:

Nil

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

云南 

市(区县):

昆明 

Country:

China

Province:

Yunnan

City:

Kunming

单位(医院):

云南省第二人民医院 

单位级别:

三级甲等 

Institution
hospital:

The Second People's Hospital of Yunnan

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

血生化

指标类型:

主要指标

Outcome:

Blood biochemistry

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

本研究为横断面研究,故无需随机方法

Randomization Procedure (please state who generates the random number sequence and by what method):

This study is a cross-sectional study, so random methods are not needed

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

N/A

Blinding:

N/A

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

通过电子邮件方式与项目负责人联系后获得

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Obtained after contacting the project leader via email

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

case record form

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2021-01-09 20:33:13